Printer Friendly

AGOURON PHARMACEUTICALS REPORTS THIRD QUARTER RESULTS

 SAN DIEGO, April 19 /PRNewswire/ -- Agouron Pharmaceuticals Inc. (NASDAQ-NMS: AGPH) today announced a net loss for the third quarter and nine months ended March 31, 1993, of $1,996,000, or $.28 per common share, and $7,522,000, or $1.08 per share, respectively. The net loss recorded in each comparable period of the prior fiscal year was $1,848,000, or $.27 per share, and $6,435,000, or $1.08 per share.
 Agouron Pharmaceuticals Inc. is a pioneer and leader of a technology permitting the rational design of novel synthetic drugs based upon the molecular structures of proteins which play key roles in human disease. Agouron is currently applying this technology to the design and development of drugs for treatment of cancer, AIDS and other serious diseases.
 AGOURON PHARMACEUTICALS INC.
 Summary Financial Information
 (In thousands, except per share amounts)
 (Unaudited)
 Three months ended Nine months ended
 March 31, March 31,
 1993 1992 1993 1992
 Statement of
 Operations Data:
 Total revenues $2,799 $2,161 $6,875 $4,734
 R&D spending $4,062 $3,296 $12,592 $9,168
 Net loss ($1,996) ($1,848) ($7,522) ($6,435)
 Net loss per share ($.28) ($.27) ($1.08) ($1.08)
 Weighted average
 number of shares 7,062 6,865 6,967 5,965
 March 31, June 30,
 1993 1992
 (Unaudited)
 Balance Sheet Data:
 Current assets $35,685 $40,173
 Total assets $41,641 $45,625
 -0- 4/19/93
 /CONTACT: Steven S. Cowell, VP & CFO, or Donna Nichols, director-Corporate Communications of Agouron Pharmaceuticals, 619-622-3000/
 (AGPH)


CO: Agouron Pharmaceuticals Inc. ST: California IN: MTC SU: ERN

BP-KJ -- SD007 -- 7592 04/19/93 16:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 19, 1993
Words:276
Previous Article:FIRST WESTERN BANCORP, INC. ANNOUNCES QUARTERLY DIVIDEND DECLARATION, RESULTS OF ANNUAL MEETING AND REORGANIZATION
Next Article:ICOS REPORTS 1993 FIRST-QUARTER RESULTS
Topics:


Related Articles
AGOURON PHARMACEUTICALS REPORTS THIRD QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS
FDA AUTHORIZES CLINICAL TESTING OF SECOND AGOURON ANTI-TUMOR DRUG
AGOURON PHARMACEUTICALS NAMES VICE PRESIDENT, CLINICAL AFFAIRS
AGOURON CEO ISSUES STATEMENT CONCERNING RECENT STOCK PRICE DECLINE
AGOURON PHARMACEUTICALS NAMES VICE PRESIDENT, REGULATORY AFFAIRS
AGOURON PHARMACEUTICALS REPORTS FISCAL 1993 FINANCIAL RESULTS
AGOURON REPORTS INTERIM RESULTS FROM PHASE I STUDIES OF ANTI-TUMOR DRUG AG331
AGOURON REPORTS PHASE I RESULTS FOR ANTI-TUMOR DRUG AG337; CLINICIANS RECOMMEND INITIATION OF PHASE II EFFICACY TRIALS
AGOURON PHARMACEUTICALS REPORTS THIRD QUARTER RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters